Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Cancer Patients

NCT00741403 is registered in ClinicalTrials.gov with Cornerstone Pharmaceuticals as lead sponsor.

NCT NCT00741403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00741403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Cancer Patients
Lead sponsor
Cornerstone Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2008
Completion date
December 31, 2016
Enrollment
39 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced malignancies, lymphoma, metastatic cancer, solid tumors